Article

Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure Among Patients with Type 1 Diabetes

2024-02-26

Abstract excerpt

Heart failure (HF) management in type 1 diabetes (T1D) is particularly challenging due to its increased prevalence and the associated risks of hospitalization and mortality, driven by diabetic cardiomyopathy. Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) offer a promising avenue for treating HF, specifically the preserved ejection fraction variant most common in T1D, but their utility is hampered by the risk...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 82975ac0-2084-565f-8381-ac8ece2688af
DOI: 10.20944/preprints202402.1417.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure Among Patients with Type 1 DiabetesDOI 10.20944/preprints202402.1417.v1Read

Sodium-glucose co-transporter 2 Inhibitors Act Independently of <i>SGLT2</i> to Confer Benefit for Heart Failure with Reduced Ejection Fraction in MiceSemantic proximity Read

How Diabetes and Heart Failure Modulate Each Other and Condition Management.Semantic proximity Read

HFpEF as the Predominant and Underrecognized Heart Failure Phenotype in Type 2 Diabetes: Evidence from the DIABET-IC StudySemantic proximity Read

Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes: An Umbrella ReviewSemantic proximity Read

SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of ActionSemantic proximity Read

Real-World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta-Analysis.Semantic proximity Read

Effect of SGLT-2 Inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Controlled TrialsSemantic proximity Read

Heart failure and diabetes - underestimated, underdiagnosed and poorly understood: A call for action.Semantic proximity Read

SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) – rationale, methodology and designSemantic proximity Read

CETP and SGLT2 inhibitor combination therapy improves glycemic controlSemantic proximity Read

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.Semantic proximity Read

Efficacy and safety of SGLT2 inhibitors in the treatment of heart failure-May raise creatinine levels in patients: A meta-analysisSemantic proximity Read